ImmunityBio Q2 Revenue Revised to $51.2M, Targets 2026 sBLA for Bladder Cancer
IBRX has more than doubled off its 52-week low of $1.95.
Summary
ImmunityBio's Q2 revenue was revised up to $51.2M from the previously reported $50.7M, driven by Anktiva sales. The company also explicitly targets a 2026 sBLA submission for QUILT-2.005 in BCG-naïve NMIBC, adding a concrete regulatory milestone to the narrative. This follows the record Q2 results and UAE marketing authorization earlier this month, reinforcing the commercial and pipeline momentum. The going concern warning and large non-cash losses remain key risks, but the upward revenue revision and clear regulatory path are incremental positives.
At the time of this announcement, IBRX was trading at $7.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1B. The 52-week trading range was $1.95 to $12.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.